balance equationreview2020-12-31
Difference 2900000 exceeds tolerance 2083600.000. Presentation or filing-vintage differences need review.
Revenue
$1.14B
Fiscal year ended 2025-12-31Operating income
$161.60M
Fiscal year ended 2025-12-31Free cash flow
Unavailable
Fiscal year ended 2025-12-31Enpro Inc. (NPO) reported revenue of $1.14B and net income of $40.50M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Enpro Inc.’s SEC filings, each linked to the filing it came from.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.14B | $1.05B | $1.06B | $1.10B | $840.40M | $800.00M | $1.21B | $1.27B | $1.10B | $1.19B |
| Cost of revenue | $655.80M | $603.90M | $632.50M | $675.90M | $512.30M | $514.50M | $801.90M | $855.60M | $716.00M | $791.90M |
| Gross profit | $487.50M | $444.80M | $426.80M | $423.30M | $328.10M | $285.50M | $403.80M | $418.50M | $385.40M | $395.80M |
| Operating income | $161.60M | $142.30M | $76.80M | $72.20M | $65.40M | $29.10M | $56.60M | $85.80M | $70.20M | -$2.50M |
| Net income | $40.50M | $72.90M | $22.20M | $205.10M | $177.90M | $177.60M | $38.30M | $19.60M | $539.80M | -$40.10M |
| Research & development | $13.30M | $10.90M | $9.50M | $10.10M | $9.80M | $9.40M | $20.60M | $22.90M | $24.50M | $28.90M |
| Weighted-average diluted shares | shares 21.20M | shares 21.10M | shares 21.00M | shares 20.90M | shares 20.80M | shares 20.50M | shares 20.80M | shares 20.90M | shares 21.80M | shares 21.60M |
| Pretax income | $57.60M | $94.40M | $37.70M | $28.30M | $66.00M | -$23.50M | $4.30M | $15.10M | $546.00M | -$68.70M |
| Income tax expense | $17.10M | $21.50M | $30.80M | $24.40M | $8.70M | -$2.50M | -$3.50M | $19.80M | $28.10M | -$28.60M |
| Diluted EPS | $1.91 | $3.45 | $1.05 | $9.83 | $8.57 | $8.64 | $1.85 | $0.94 | $24.76 | $-1.86 |
| Selling, general & administrative | $323.40M | $296.30M | $284.20M | $282.80M | $260.30M | $230.20M | $314.90M | $311.60M | $298.30M | $302.70M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $114.70M | $236.30M | $369.80M | $334.40M | $338.10M | $229.50M | $121.20M | $129.60M | $189.30M | $111.50M |
| Total assets | $2.66B | $2.49B | $2.50B | $2.65B | $2.97B | $2.08B | $2.04B | $1.72B | $1.89B | $1.55B |
| Current assets | $437.70M | $512.30M | $650.30M | $684.20M | $804.70M | $579.00M | $749.50M | $732.10M | $819.60M | $524.90M |
| Total liabilities | $1.12B | $1.06B | $1.07B | $1.23B | $1.65B | $956.70M | $1.12B | $858.10M | $983.30M | $1.19B |
| Current liabilities | $188.70M | $198.00M | $196.40M | $211.50M | $386.30M | $202.00M | $313.60M | $292.00M | $268.10M | $303.00M |
| Total equity incl. NCI | $1.54B | $1.43B | $1.41B | $1.40B | $1.27B | $1.08B | $896.60M | $857.70M | $902.80M | $358.50M |
| Temporary (mezzanine) equity | $0 | $0 | $17.90M | $17.90M | $50.10M | $48.40M | $28.00M | $0 | Unavailable | Unavailable |
| Inventory | $153.80M | $138.80M | $142.60M | $151.90M | $135.90M | $139.10M | $157.10M | $174.20M | $204.10M | $175.40M |
| Accounts receivable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Goodwill | $1.06B | $896.20M | $808.40M | $863.80M | $948.00M | $605.10M | $485.30M | $322.10M | $324.10M | $201.50M |
| Long-term debt | $655.10M | $624.10M | $638.70M | $775.10M | $963.90M | $487.50M | $625.20M | $462.50M | $618.30M | $424.80M |
| Accounts payable | $71.60M | $66.00M | $68.70M | $73.40M | $72.00M | $69.80M | $82.70M | $96.40M | $130.70M | $102.90M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Capital expenditures | $42.00M | $29.10M | $33.90M | $29.40M | $14.90M | $13.40M | $21.60M | $36.10M | $30.30M | $35.80M |
| Investing cash flow | -$316.90M | -$241.50M | -$7.40M | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Financing cash flow | -$17.40M | -$50.50M | -$170.90M | -$402.10M | $618.20M | -$167.30M | $123.80M | -$252.40M | $118.50M | Unavailable |
| Net change in cash | -$121.60M | -$133.50M | $35.40M | -$3.70M | $108.60M | $108.30M | -$8.40M | -$59.70M | $77.80M | $8.10M |
| Stock-based compensation | $13.50M | $12.00M | $9.80M | $6.50M | $5.00M | $5.40M | $6.80M | $6.50M | $9.50M | $5.10M |
| Common dividends paid | $26.20M | $25.30M | $24.30M | $23.40M | $22.40M | $21.70M | $20.90M | $20.30M | $19.00M | $18.10M |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | $0 | $5.30M | $15.00M | $50.00M | $11.50M | $30.40M |
| Depreciation & amortization | $102.80M | $100.30M | $94.50M | $103.10M | $63.80M | $56.60M | $67.90M | $66.10M | $58.60M | $57.10M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Gross margin | 42.6% | 42.4% | 40.3% | 38.5% | 39.0% | 35.7% | 33.5% | 32.8% | 35.0% | 33.3% |
| Operating margin | 14.1% | 13.6% | 7.3% | 6.6% | 7.8% | 3.6% | 4.7% | 6.7% | 6.4% | -0.2% |
| FCF margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| SBC / revenue | 1.2% | 1.1% | 0.9% | 0.6% | 0.6% | 0.7% | 0.6% | 0.5% | 0.9% | 0.4% |
| Current ratio | 2.32x | 2.59x | 3.31x | 3.23x | 2.08x | 2.87x | 2.39x | 2.51x | 3.06x | 1.73x |
| Revenue YoY growth | 9.0% | -1.0% | -3.6% | 30.8% | 5.0% | -33.6% | -5.4% | 15.7% | -7.3% | Unavailable |
| Net margin | 3.5% | 7.0% | 2.1% | 18.7% | 21.2% | 22.2% | 3.2% | 1.5% | 49.0% | -3.4% |
| R&D / revenue | 1.2% | 1.0% | 0.9% | 0.9% | 1.2% | 1.2% | 1.7% | 1.8% | 2.2% | 2.4% |
| CapEx / revenue | 3.7% | 2.8% | 3.2% | 2.7% | 1.8% | 1.7% | 1.8% | 2.8% | 2.8% | 3.0% |
| Long-term debt / equity | 0.42x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | 0.54x | Unavailable | Unavailable |
| Effective tax rate | 29.7% | 22.8% | 81.7% | 86.2% | 13.2% | Unavailable | -81.4% | 131.1% | 5.1% | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NPO in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing
Reconciliation checks needing review
2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
balance equationreview2019-12-31
Difference 9700000 exceeds tolerance 2035100.000. Presentation or filing-vintage differences need review.